Spero Therapeutics' earnings of $0.02 fell short of expectations, while profits exceeded forecasts.

According to Spero Therapeutics (NASDAQ: SPRO) report, the earnings per share for the first quarter came in at -$0.380, which is $0.02 worse than analysts' expectations of -$0.360. The reported earnings for this quarter were $15.04 million, while analysts had anticipated $4.5 million.

Spero Therapeutics' stock closed at $0.86, indicating a staggering decline of -16.500% over the past three months and a drop of -49.240% over the last year. In the last 90 days, Spero Therapeutics has seen 2 instances of positive earnings per share and 1 instance of negative earnings per share. Explore how Spero Therapeutics' stock price reacted to previous earnings reports. According to InvestingPro, the company's financial health rating is "Good performance." Check out the latest earnings reports and all financial information about Spero Therapeutics here. Stay updated on all developments related to balance sheets by visiting the Investing.com Earnings Calendar.